Gefitinib in heavily pretreated non small cell lung cancer: Results of the expanded access program in Eastern France.

被引：0
|
作者：
Spaeth, D
Deplanque, G
Favrot, N
Paillot, N
Lang, MP
Cuguiliere, A
Seigneur, J
机构：
[1] Ctr Alexis Vautrin, Nancy, France
[2] Dept Oncol, Scy Chazelles, France
[3] Ctr GF Leclerc, Dijon, France
[4] Serv Pneumol, Metz, France
[5] Serv Pneumol, Mt St Martin, France
[6] HIA Legouest, Metz, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7323
引用
收藏
页码：696S / 696S
页数：1
相关论文
共 50 条
  • [1] Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)
    Tamburini, E.
    Tassinari, D.
    Pasquini, E.
    Papi, M.
    Possenti, C.
    Drudi, F.
    Castellani, C.
    Santelmo, C.
    Carloni, F.
    Ravaioli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Gefitinib in treatment of advanced non-small-cell lung cancer as a last treatment option on an Expanded Access Program
    Zemanova, M
    Petruzelka, L
    Honova, H
    Dvorak, J
    Safanda, M
    Mares, P
    Tomancova, V
    LUNG CANCER, 2004, 45 : S82 - S82
  • [3] Gefitinib in treatment of advanced non-small-cell lung cancer as a last treatment option on an Expanded Access Program
    Zemanova, M
    Petruzelka, L
    Honova, H
    Dvorak, J
    Safanda, M
    Mares, P
    Tomancova, V
    LUNG CANCER, 2004, 45 : S82 - S83
  • [4] Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme
    Gridelli, C
    Rossi, A
    Maione, P
    Musto, L
    Del Gaizo, F
    Airoma, G
    BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [5] Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Govindan, Ramaswamy
    Natale, Ronald
    Wade, James
    Herbst, Roy
    Krebs, Annetta
    Reiling, Richard
    Hensing, Thomas
    Wozniak, Antoinette
    Belani, Chandra P.
    Kelly, Karen
    Ochs, Judith
    LUNG CANCER, 2006, 53 (03) : 331 - 337
  • [6] Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Thomas, Sheeba K.
    Fossella, Frank V.
    Liu, Diane
    Schaerer, Rainell
    Tsao, Anne S.
    Kies, Merrill S.
    Pisters, Katherine M.
    Blumenschein, George R., Jr.
    Glisson, Bonnie S.
    Lee, J. Jack
    Herbst, Roy S.
    Zinner, Ralph G.
    CLINICAL LUNG CANCER, 2006, 7 (05) : 326 - 331
  • [7] Gefitinib for patients with advanced non-small cell lung cancer treated on the expanded access program: a single institution experience
    de Souza Cruz, Marcelo Rocha
    Katz, Artur
    Gansl, Rene Claudio
    Tabacoff, Jacques
    Smaletz, Oren
    Simon, Sergio Daniel
    EINSTEIN-SAO PAULO, 2006, 4 (03): : 207 - 212
  • [8] Gefitinib ('Iressa', ZD1839) in heavily pretreated patients with metastatic non-small-cell lung cancer
    Martín-Algarra, S
    Gurpide, A
    Lopez-Picazo, JM
    BRITISH JOURNAL OF CANCER, 2003, 89 : S30 - S30
  • [9] Initial safety results of an expanded access program (EAP) of erlotinib in non-small cell lung cancer (NSCLC).
    Reck, M.
    Perng, R.
    Groen, H.
    Riska, H.
    Pirker, R.
    Sederholm, C.
    Caspar, C.
    Boyer, M.
    Berzinec, P.
    Allan, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 411S - 411S
  • [10] Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP).
    Reding, RB
    Natale, R
    Wade, J
    Herbst, R
    Hensing, T
    Belani, CP
    Kelly, K
    Ochs, J
    Govindan, R
    Wozniak, A
    Krebs, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 643S - 643S
12345